Researchers examined trends in adherence to various treatment among patients with psoriasis using data from a large health insurance database. For which therapy had the highest odds for adherence, read more.

News

News
Thursday, July 7, 2016
Families with a history of cardiovascular disease increase the risk of first-time major adverse cardiovascular events occurring in young adults with psoriasis.
News
Monday, June 27, 2016
Psoriasis patients, treated with ixekizumab (Taltz), experienced short- and long-term improvements in work productivity that could lead to a reduced productivity-related cost burden, according to a new study published online in JAMA Dermatology.
News
Friday, June 10, 2016
Results from 3 Phase 3 studies, published in The New England Journal of Medicine, demonstrated the safety and efficacy of ixekizumab (Taltz) for the treatment of moderate to severe plaque psoriasis.
News
Thursday, June 9, 2016
Positive, top-line results from the second Phase 3 Oral Psoriatic Arthritis Trial (OPAL) Beyond study of tofacitinib citrate (Xeljanz) were recently released.